SELLAS Life Sciences (SLS) Return on Invested Capital (2013 - 2017)

SELLAS Life Sciences (SLS) posted quarterly Return on Invested Capital of 0.01% for Q4 2017, down 319.91% quarter-over-quarter from 0.0% in Q3 2017.

SELLAS Life Sciences (SLS) Return on Invested Capital (2013 - 2017) Analysis & Trends

SELLAS Life Sciences (SLS) has reported Return on Invested Capital for 3 consecutive years, with 0.01% the latest figure, recorded in Q4 2017.

In Q4 2017, Return on Invested Capital changed N/A year-over-year to 0.01%; the TTM figure through Dec 2017 stood at 0.01% (changed N/A YoY), while the FY2017 annual figure was 0.05%, changed 0.0% from the prior year.
Return on Invested Capital eased to 0.01% in Q4 2017 per SLS's latest filing, from 0.0% in the prior quarter.
Across five years, Return on Invested Capital topped out at 0.0% in Q3 2017 and bottomed at 0.11% in Q4 2013.
Historically, Return on Invested Capital has averaged 0.04% across 3 years, with a median of 0.04% in 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.04%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.05%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.35%
10	SELLAS Life Sciences	2.32 Bn	2.18 Bn	-	-

Download Data